← Oncology Approval Tracker

FDA DECISION ·

Lunsumio Velo

mosunetuzumab-axgb · Genentech

Accelerated approvalNew formulationFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous treatment of adults with relapsed or refractory follicular lymphoma after two or more systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The new route gives this CD20×CD3 bispecific an additional administration option under accelerated approval.

What research teams should watch

Separate Lunsumio Velo and IV Lunsumio order sets and train teams on route-specific step-up dosing and cytokine release syndrome management.

PRIMARY RECORDS

Sources